E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
allergic asthma and allergen-induced asthma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001705 |
E.1.2 | Term | Allergic asthma |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003638 |
E.1.2 | Term | Atopic asthma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the efficacy and safety of multiple inhaled daily doses of TPI ASM8 in steroid-naïve asthmatic adults with atopy. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Men and women 18 to 65 years of age; non-smoking, steroid-naive, (i.e.. those who are not currently on corticosteroid or those who have not taken any oral/ inhaled/ ophthalmic or injectable corticosteroid within 60 days prior to start of the study); and generally in good health; • Intermittent or persistent mild to moderate allergic asthma as defined by ATS/ ERS criteria ((American Thoracic Society Lung function testing, 1991); • History of episodic wheeze and shortness of breath; • Forced expiratory volume in 1 second (FEV1) at baseline at least 70% of the predicted value; • Able to comprehend and follow all required study procedures; • Willing and able to sign an REB/IEC-approved informed consent form; • Subjects must not be taking any other regular anti-asthmatic medication except for the short-acting B2-agonist bronchodilator (e.g. salbutamol/albuterol) on an as needed basis; • Positive 5’AMP challenge at baseline (AMP-PC20 ≤ 60 mg/mL); • Positive skin-prick test to at least one of common aeroallergens (including cat fur and dander, house dust mite, mixed grass pollen); • Positive allergen-induced early (fall equal to or greater than 20% in FEV1 at 0-3 hrs following allergen challenge) and late (fall in FEV1 equal to or greater than 15% at 3-7 hrs) airway response (Dual responders).
|
|
E.4 | Principal exclusion criteria |
• Significant acute or chronic medical, neurologic, cardiovascular or psychiatric illness; • Known coagulopathy; • Asthma exacerbation or respiratory infection in the preceding 6 weeks; • Use of oral / injectable corticosteroids within the last 60 days or currently on any anti-asthmatic drugs, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants. (Intermittent doses of short-acting β2-agonist are allowed); • Investigational drug use within 30 days; • Any clinically significant abnormality on physical examination or on screening laboratory determinations; • A >20% fall in FEV1 or FVC with baseline saline in the first AMP challenge during the screening period (Day –14). • Blood draws of 100 mL or more within 45 days prior to enrolment in the study. • Ongoing use of tobacco products of any kind or previous usage within the past 12 months or past history of greater than or equal to 10 pack years • Pregnant or lactating women; women actively seeking pregnancy or who are unwilling to use adequate contraception.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Safety • Vital signs include heart rate (preferably taken after a 10-15 min rest), respiratory rate, blood pressure, supine and standing and body temperature (oral or tympanic). Weight (kg) and height (cm) will be measured only at screening. • Adverse Events (AEs) & Serious Adverse Events (SAEs): An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation subject who receives a pharmaceutical product at any dose, whether or not there is a causal relationship with the investigational treatment. An AE could therefore be any unfavourable or unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. This definition includes intercurrent illnesses or injuries and exacerbation of pre-existing conditions. An unexpected AE is an AE not identified in nature, severity, or frequency in the current Investigator Brochure. An SAE is defined as any untoward medical occurrence that 1) results in death; 2) is life threatening (i.e., the subject was, in the opinion of the investigator, at immediate risk of death from the event as it occurred); 3) requires or prolongs hospitalization; 4) results in persistent or significant disability or incapacity (i.e., the event causes a substantial disruption of a person’s ability to conduct normal life functions); 5) is a congenital anomaly or birth defect in the offspring of the treated subject; and 6) is an important and significant medical event that, based upon appropriate medical judgment, may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes defining SAE. • Concomitant medications • Routine laboratory (haematology and chemistry), complement (Bb split product) and urinalysis, CRP • Total serum IgE level and immunogenicity profile • Single breath lung diffusion capacity (DLCO).
2. Allergen-induced late airway response (LAR), maximum decrease in FEV1 (%) on Day 14.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 7 |